Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

類似資料

• Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4
  著者:: Holmgaard, Rikke B, 等
  出版事項: (2013)
• Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
  著者:: Holmgaard, Rikke B., 等
  出版事項: (2016)
• Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
  著者:: Holmgaard, Rikke B, 等
  出版事項: (2014)
• Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy
  著者:: Johnson, Burles A, 等
  出版事項: (2009)
• Indoleamine 2,3-dioxygenase and tumor-induced tolerance
  著者:: Munn, David H., 等
  出版事項: (2007)